INTRODUCTION: We review the current evidence for the role of low-dose rate brachytherapy (PB) in patients with low- or intermediate-risk prostate cancer using a systematic review of the literature.
METHODS: We searched MEDLINE and EMBASE (from January 1996 to October 2011), the Cochrane Library, relevant guideline web-sites, and websites for meetings specific for genitourinary diseases.
RESULTS: Ten systematic reviews and 55 single-study papers met the pre-planned study selection criteria. In the end, 36 articles were abstracted and analyzed for this systematic review. There is no evidence for a difference in efficacy between PB and external beam radiation therapy (EBRT), or between PB and radical prostatectomy (RP). During the 6 months to 3 years after treatment, PB was associated with less urinary incontinence and sexual impotency than RP, and RP was associated with less urinary irritation and rectal morbidity than PB. However, these differences diminished over time. PB conferred less risk of impotency and rectal morbidity in the three years after treatment than EBRT. Iodine-125 and alladium-103 did not differ with respect to biochemical relapse-free survival and patient-reported outcomes.
CONCLUSIONS: PB alone is a treatment option with equal efficacy to EBRT or RP alone in patients with newly diagnosed low- or intermediate-risk prostate cancer who require or choose active treatment.
Written by:
Rodrigues G1, Yao X2, Loblaw DA3, Brundage M4, Chin JL5 Are you the author?
1London Health Sciences Centre, Department of Oncology, Western University, London, ON; 2Program in Evidence-based Care, McMaster University, Hamilton, ON; 3Department of Radiation Oncology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, ON; 4Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University; 5Division of Urology, London Health Sciences Centre, Division of Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, ON.
Reference: Can Urol Assoc J. 2013 Nov;7(11-12):463-470
PubMed Abstract
PMID: 24381672
UroToday.com Prostate Cancer Section
